India’s first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine (Pneumonia vaccine) has received the approval from Drug Controller General of India (DCGI). It will be utilized for active immunization against invasive disease and pneumonia caused by “Streptococcus pneumonia” among infants.
Pneumococcal Polysaccharide Conjugate Vaccine (Pneumonia vaccine) has been developed by Serum Institute of India Pvt Ltd, Pune. It is India’s first indigenously developed vaccine in the field of pneumonia. With the DCGI’s approval, Serum Institute of India has been granted permission to manufacture the vaccine domestically.
On February 1, 2026. In a gripping men's singles final at the Australian Open 2026,…
The Union Budget 2026-27, presented by Nirmala Sitharaman on 1 February 2026, marks a decisive…
Preparing for Banking, SSC, RBI, NABARD, and other competitive exams requires a strong grasp of…
The Union Budget 2026 has delivered one of the strongest signals yet of India’s changing…
Union Budget 2026-27 has placed sports firmly within India’s growth and employment strategy. While presenting…
The Union Budget 2026-27 has placed healthcare at the centre of India’s development agenda. With…